Alimta pemetrexed regulatory update

EMEA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Alimta to treat malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Earlier this year, FD...